• Kymera Therapeutics completed enrollment in its KT-621 Phase 2b atopic dermatitis trial, with data expected by year-end 2026.
• Phase 3 atopic dermatitis trials are planned to begin by mid-2027; the KT-621 program is six months ahead of schedule.
• The ongoing KT-621 Phase 2b asthma trial is expected to report data in late 2027.
• Earlier Phase 1b results showed a 63% mean EASI reduction, with no serious or severe adverse events.
• KT-579, an oral IRF5 degrader, is scheduled to enter the LUMORA Phase 1b lupus trial by early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.